Get Started
Multiple Sclerosis Curricula
Step 1
These independent CME activities are supported by educational grants from Biogen MA, Inc.,Celgene Corporation, Genzyme, a Sanofi Company and Novartis Pharmaceuticals Corporation.



      Neurology Mastery in
   Multiple Sclerosis
  1. Course List
Editor-in-Chief
James D. Bowen, MD
  • Medical Director, Multiple
  •   Sclerosis Center
  • Swedish Neuroscience
  •   Institute
  • Seattle, Washington

  • Contributing Editor
    Enrique Alvarez, MD, PhD, MSCI
  • Assistant Professor
  • Department of Neurology
  • University of Colorado, School of Medicine
  • Aurora, Colorado

  • John A. Schafer, MD, FAAN
  • Director, Mercy MS Center
  • Medical Director, MS Achievement Center
  • Department of Neurology
  • Mercy Medical Group / Dignity HealthCarmichael, California

  • Faculty
    Maria Houtchens, MD
  • Assistant Professor
  • Department of Neurology
  • Brigham and Women's Hospital
  • Auburndale, Massachusetts

  • Jacqueline A. Nicholas, MD, MPH
  • Clinical Neuroimmunologist
  • Department of Neurology
  • OhioHealth Neurological Physicians
  • Columbus, Ohio

  • Bardia Nourbakhsh, MD, MAS
  • Assistant Professor
  • Department of Neurology
  • Johns Hopkins University
  • Baltimore, Maryland

  • Bianca Weinstock-Guttman, MD
  • Professor of Neurology
  • Director, Jacobs MS Center for Treatment and Research
  • Director, Jacobs Pediatric MS Center
  • University of Buffalo
  • Jacobs School of Medicine and Biomedical Sciences
  • Buffalo, New York
  • Disclosure Information
    James D. Bowen, MD   received financial support for research activities from Acorda Therapeutics, Alexion, Allergan, Biogen, EMD Serono Inc, Genzyme, a Sanofi Company, Genentech, GlaxoSmithKline, Novartis, Opexa, Osmotica, Roche, sanofi-aventis U.S. LLC, and Xenoport; has received consulting fees from Acorda Therapeutics, Biogen, EMD Serono Inc, Genzyme, a Sanofi Company, Genentech, Novartis, and Teva Neuroscience; and has received honoraria from Acorda Therapeutics, Biogen, EMD Serono Inc, Genentech, Novartis, Pfizer Inc, and Teva Neuroscience.

    Enrique Alvarez, MD, PhD, MSCI   has received consulting fees from Biogen Idec, Genentech, Genzyme, Novartis Pharmaceuticals Corporation, and Teva Neuroscience and has conducted contracted research for Acorda, Biogen Idec, Genentech, and Novartis Pharmaceuticals Corporation.

    John A. Schafer, MD, FAAN   has received honoraria from Acorda Therapeutics, Biogen-Idec, EMD-Serono, Genentech, Inc., Genzyme Corporation, Novartis Pharmaceuticals Corporation, and TEVA Neuroscience; and has conducted contract research for Bayer AG, Biogen-Idec, Genenctech, Inc., Mallinckrodt Pharmaceuticals, Novartis Pharmaceutcials Corporation, and TEVA Pharmaceuticals.

    Maria Houtchens, MD   has received honoraria from Genzyme, a Sanofi Company and Teva Pharmaceuticals; has received consulting fees from Biogen Inc., Genzyme, a Sanofi Company, and Teva Pharmaceuticals; and conducted contracted research for Biogen Inc., and Genzyme, a Sanofi Company.

    Jacqueline A. Nicholas, MD, MPH   has received honoraria from Biogen Idec, Genentech, Inc., Genzyme, a Sanofi Company and Novartis Pharmaceuticals Corporation; and conducted contracted research for Biogen Idec, Genzyme, a Sanofi Company, and Novartis Pharmaceuticals Corporation.

    Bardia Nourbakhsh, MD, MAS   has no relevant relationships to disclose.

    Bianca Weinstock-Guttman, MD   has received honoraria from Biogen Idec, Genentech, Inc., Novartis Pharmaceuticals Corporation, Sanofi, and Teva Pharmaceuticals; received consulting fees from Biogen Idec, Takeda, and Teva Pharmaceuticals; and conducted contracted research for Biogen Idec, EMD Serono, Novartis Pharmaceuticals Corporation, and Sanofi.